Chimerix, Inc.

310 articles about Chimerix, Inc.

• Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

  1/25/2021

  Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,764,750 shares of common stock. As a result, the Company issued a total of 13,529,750 shares i

• Chimerix Announces Pricing of Public Offering of Common Stock

  1/21/2021

  Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of $8.50 per share

• Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock

  1/19/2021

  Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today that it intends to offer and sell, subject to market and other conditions, up to $75,000,000 of shares of its common stock in an underwritten public offering

• 

  Starting the Year Dropping Cash - Two Companies Scooped Up This Week

  1/8/2021

  Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.

• Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

  1/8/2021

  Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million

• Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference

  1/6/2021

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2021 Conference made available on Monday, January 11, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations

• Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for SmallpoxFDA Grants Priority Review and Sets PDUFA Date for April 7, 2021

  12/7/2020

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that the U.S. Food and Drug Administration has accepted the filing of a New Drug Application for brincidofovir as a medical countermeasure for smallpox.

• Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference

  11/5/2020

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.

• Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update

  11/5/2020

  Completed Rolling NDA Submissions for Both BCV Tablet and SuspensionFormulations as Medical Countermeasure for Smallpox

• Chimerix to Participate in Upcoming Investor Conferences

  9/10/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September

• Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update

  8/10/2020

  Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an operational update.

• Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020

  8/3/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview. To access the live conference call, please dial (877) 354-4056 (domestic)

• Chimerix Appoints Allen Melemed, M.D. as Chief Medical OfficerFormer Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise

  6/22/2020

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Allen Melemed, M.D., M.B.A., as Chief Medical Officer.

• Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series

  6/18/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:05 p.m. ET.

• Chimerix to Present at Jefferies Virtual Healthcare Conference

  5/28/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of C

• Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update

  5/7/2020

  DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic

• Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

  4/29/2020

  Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood Coagulation Disorders Associated with COVID-19

• Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

  4/28/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.

• Chimerix to Present at Cowen and Company 40th Annual Health Care Conference

  2/26/2020

  DURHAM, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, 2020 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the Investor Relations s

• Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update

  2/25/2020

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided an operational update.